世界のがんワクチン市場は、2024年の106億1000万ドルから2032年には204億7000万ドルに達すると予測され、CAGRは8.6%になる見込みです。がんワクチン市場の急速な成長は、がんの有病率の上昇、免疫療法の技術的進歩、世界的な予防医療の採用の増加に支えられています。子宮頸がん患者に対するHPVワクチンの採用の増加と、ネオアンチゲンベースのmRNAワクチンの出現が、市場の成長に貢献する要因です。研究開発への投資や、モデルナの腫瘍領域における共同研究などの戦略的パートナーシップにより、がんワクチン分野のイノベーションが加速しています。堅調な製品パイプラインも、今後数年間の市場成長に貢献する可能性があります。
目次
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED & REGIONAL SEGMENTATION
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 MARKET ESTIMATION
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
2.2.3 TOP-DOWN APPROACH
2.3 MARKET GROWTH RATE PROJECTION
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 CANCER VACCINES MARKET OVERVIEW
4.2 NORTH AMERICA: CANCER VACCINES MARKET, BY TECHNOLOGY AND COUNTRY (2023)
4.3 CANCER VACCINES MARKET SHARE, BY TYPE, 2024 VS. 2032
4.4 CANCER VACCINES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increased investments in neoantigen cancer vaccine R&D
5.2.1.2 Technological advancements in immunotherapy
5.2.1.3 Increasing awareness and preventive healthcare measures
5.2.1.4 Rising cancer incidence globally
5.2.2 RESTRAINTS
5.2.2.1 High development and manufacturing costs
5.2.2.2 Lengthy clinical trial processes & vaccine hesitancy and limited adoption
5.2.3 OPPORTUNITIES
5.2.3.1 Collaborations and strategic partnerships
5.2.3.2 Incorporation of AI and big data
5.2.4 CHALLENGES
5.2.4.1 Personalized medicine and heterogeneity of cancer types
5.2.4.2 Competition from alternative therapies
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESS
5.4 VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.5.1 RAW MATERIAL PROVIDERS
5.5.2 PRODUCT PROVIDERS
5.5.3 END USERS
5.5.4 REGULATORY LANDSCAPE
5.6 TECHNOLOGY ANALYSIS
5.6.1 KEY TECHNOLOGIES
5.6.1.1 mRNA-based vaccines
5.6.1.2 Dendritic cell vaccines
5.6.1.3 Recombinant vector-based vaccines
5.6.2 COMPLEMENTARY TECHNOLOGIES
5.6.2.1 Artificial Intelligence (AI) and Machine Learning (ML)
5.6.2.2 Adjuvants for immuno-stimulation
5.6.3 ADJACENT TECHNOLOGIES
5.6.3.1 CAR T-cell therapy
5.6.3.2 CRISPR-based gene editing
5.7 PATENT ANALYSIS
5.7.1 METHODOLOGY
5.7.2 NUMBER OF PATENTS FILED
5.7.3 INNOVATIONS AND PATENT APPLICATIONS
5.8 PRICING ANALYSIS
5.8.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, 2021-2023
5.8.2 AVERAGE SELLING PRICE, BY REGION, 2023
5.9 KEY CONFERENCES & EVENTS, 2024-2O25
5.10 REGULATORY LANDSCAPE
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10.2 REGULATORY FRAMEWORK
5.10.2.1 North America
5.10.2.2 Europe
5.10.2.3 Asia Pacific
5.11 INVESTMENT & FUNDING SCENARIO
5.12 PORTER'S FIVE FORCES ANALYSIS
5.12.1 INTENSITY OF COMPETITIVE RIVALRY
5.12.2 BARGAINING POWER OF SUPPLIERS
5.12.3 BARGAINING POWER OF BUYERS
5.12.4 THREAT OF SUBSTITUTES
5.12.5 THREAT OF NEW ENTRANTS
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS
5.13.2 KEY BUYING CRITERIA
5.14 TRADE ANALYSIS
5.14.1 IMPORT DATA FOR HS CODE 300241
5.14.2 EXPORT DATA FOR HS CODE 300241
5.15 IMPACT OF AI/GEN AI ON CANCER VACCINES MARKET
5.16 PIPELINE ANALYSIS
6 CANCER VACCINES MARKET, BY TYPE
6.1 INTRODUCTION
6.2 PREVENTIVE VACCINES
6.2.1 NATIONAL IMMUNIZATION PROGRAMS & BIOTECHNOLOGY INNOVATIONS TO DRIVE MARKET GROWTH
6.3 THERAPEUTIC VACCINES
6.3.1 NEOANTIGEN CANCER VACCINES
6.3.1.1 Personalized nature of neoantigen cancer vaccines to propel market growth
6.3.2 OTHER THERAPEUTIC VACCINES
7 CANCER VACCINES MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 CELL-BASED VACCINES
7.2.1 ADVANCEMENTS IN MANUFACTURING PROCESSES TO DRIVE MARKET GROWTH
7.3 RECOMBINANT VACCINES
7.3.1 GLOBAL VACCINATION INITIATIVES TO PROPEL MARKET
7.4 OTHER VACCINE TECHNOLOGIES
8 CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION
8.1 INTRODUCTION
8.2 INTRAMUSCULAR ROUTE
8.2.1 TECHNOLOGICAL ADVANCEMENTS IN VACCINE DELIVERY TO SUPPORT MARKET GROWTH
8.3 OTHER ROUTES OF ADMINISTRATION
9 CANCER VACCINES MARKET, BY INDICATION
9.1 INTRODUCTION
9.2 CERVICAL & RELATED CANCERS
9.2.1 RISING CERVICAL CANCER PREVALENCE TO SUPPORT MARKET GROWTH
9.3 OTHER INDICATIONS
10 CANCER VACCINES MARKET, BY END USER
10.1 INTRODUCTION
10.2 HOSPITALS
10.2.1 RISING CANCER PREVALENCE TO SUPPORT MARKET GROWTH
10.3 SPECIALTY CLINICS & CENTERS
10.3.1 INCREASING AWARENESS AND ACCESS TO PROPEL MARKET
11 CANCER VACCINES MARKET, BY REGION
11.1 INTRODUCTION
11.2 ASIA PACIFIC
11.2.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.2.2 CHINA
11.2.2.1 Government support & strategic initiatives by key players to strengthen biotechnology sector in China
11.2.3 JAPAN
11.2.3.1 Government initiatives for vaccines to boost market
11.2.4 INDIA
11.2.4.1 Growth of biotechnology sector and development of new vaccines to drive market
11.2.5 SOUTH KOREA
11.2.5.1 Commitment to cancer immunotherapy to expand cancer vaccine sector
11.2.6 REST OF ASIA PACIFIC
11.3 NORTH AMERICA
11.3.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.3.2 US
11.3.2.1 US to dominate North American market during forecast period
11.3.3 CANADA
11.3.3.1 Increasing government funding for vaccine research to drive market growth in Canada
11.4 EUROPE
11.4.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.4.2 GERMANY
11.4.2.1 Increasing investments by key players and growing funding from government organizations to drive market
11.4.3 UK
11.4.3.1 Rising investments in vaccine development to boost market growth
11.4.4 FRANCE
11.4.4.1 Support for biotechnology and research to drive market growth
11.4.5 ITALY
11.4.5.1 Government initiatives for vaccine development to boost market growth
11.4.6 SPAIN
11.4.6.1 Increasing investments in vaccine development by government and private organizations to support market growth
11.4.7 REST OF EUROPE
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.2.1 Proactive healthcare policies to support market growth
11.5.3 MEXICO
11.5.3.1 Government commitment to immunization programs to fuel growth
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
11.6.2 GCC COUNTRIES
11.6.3 REST OF MIDDLE EAST
11.7 AFRICA
11.7.1 INCREASING INVESTMENTS IN CANCER VACCINE IMMUNIZATION PROGRAMS TO SUPPORT MARKET GROWTH
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CANCER VACCINES MARKET
12.3 REVENUE ANALYSIS, 2019-2023
12.4 MARKET RANKING, 2023 AND 2032
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.5.5.1 Company footprint
12.5.5.2 Region footprint
12.5.5.3 Type footprint
12.5.5.4 Technology footprint
12.5.5.5 Route of administration footprint
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
12.7 COMPANY VALUATION & FINANCIAL METRICS
12.7.1 FINANCIAL METRICS
12.7.2 COMPANY VALUATION
12.8 BRAND/PRODUCT COMPARISON
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES & APPROVALS
12.9.2 DEALS
12.9.3 EXPANSIONS
13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 MERCK & CO., INC.
13.1.1.1 Business overview
13.1.1.2 Products offered
13.1.1.3 Recent developments
13.1.1.3.1 Deals
13.1.1.3.2 Expansions
13.1.1.4 MnM view
13.1.1.4.1 Key strengths
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses & competitive threats
13.1.2 GSK PLC.
13.1.2.1 Business overview
13.1.2.2 Products offered
13.1.2.3 Recent developments
13.1.2.3.1 Product approvals
13.1.2.4 MnM view
13.1.2.4.1 Key strengths
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses & competitive threats
13.1.3 DENDREON PHARMACEUTICALS LLC. (SANPOWER GROUP)
13.1.3.1 Business overview
13.1.3.2 Products offered
13.1.3.3 MnM view
13.1.3.3.1 Key strengths
13.1.3.3.2 Strategic choices
13.1.3.3.3 Weaknesses & competitive threats
13.1.4 JW CREAGENE (JW SHINYAK)
13.1.4.1 Business overview
13.1.4.2 Products offered
13.1.5 SERUM INSTITUTE OF INDIA PVT. LTD.
13.1.5.1 Business overview
13.1.5.2 Products offered
13.1.5.3 Recent developments
13.1.5.3.1 Product launches
13.1.5.3.2 Deals
13.1.6 VERITY PHARMACEUTICALS, INC.
13.1.6.1 Business overview
13.1.6.2 Products offered
13.1.6.3 Recent developments
13.1.6.3.1 Product approvals
13.1.7 WANTAI BIOPHARM
13.1.7.1 Business overview
13.1.7.2 Products offered
13.1.8 SHANGHAI ZERUN BIOTECH CO., LTD. (WALVAX BIOTECHNOLOGY CO., LTD.)
13.1.8.1 Business overview
13.1.8.2 Products offered
13.1.8.3 Recent developments
13.1.8.3.1 Product approvals
13.1.9 VACCINOGEN
13.1.9.1 Business overview
13.1.9.2 Products offered
13.2 OTHER PLAYERS (COMPANIES WITH PRODUCTS UNDER CLINICAL STUDIES)
13.2.1 BIONTECH
13.2.1.1 BioNTech: Products under clinical studies
13.2.2 GRITSTONE BIO
13.2.2.1 Gritstone Bio: Products under clinical studies
13.2.3 OSE-IMMUNO
13.2.3.1 OSE-Immuno: Products under clinical studies
13.2.4 OBI PHARMA
13.2.4.1 OBI Pharma: Products under clinical studies
13.2.5 SHANGHAI BOVAX BIOTECHNOLOGY CO., LTD.
13.2.5.1 Shanghai Bovax Biotechnology: Products under clinical studies
13.2.6 MODERNA INC.
13.2.6.1 Moderna: Products under clinical studies
13.2.7 BEIJING SINOCELL BIOTECHNOLOGY GROUP CO., LTD.
13.2.7.1 Beijing Sinocell Biotechnology Group: Products under clinical studies
13.2.8 GREENWICH LIFESCIENCES, INC.
13.2.8.1 Greenwich LifeSciences: Products under clinical studies
13.2.9 ASTON SCI. INC.
13.2.9.1 Aston Sci.: Products under clinical studies
13.2.10 TRANSGENE
13.2.10.1 Transgene: Products under clinical studies
13.2.11 SELLAS LIFE SCIENCES GROUP INC.
13.2.11.1 Sellas Life Sciences Group: Products under clinical studies
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
List of Tables
TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
TABLE 2 CANCER VACCINES MARKET: RISK ASSESSMENT ANALYSIS
TABLE 3 KEY RAW MATERIAL PROVIDERS IN CANCER VACCINES MARKET
TABLE 4 KEY PRODUCT PROVIDERS IN CANCER VACCINES MARKET
TABLE 5 KEY END USERS IN CANCER VACCINES MARKET
TABLE 6 KEY REGULATORY BODIES IN CANCER VACCINES MARKET
TABLE 7 NUMBER OF PATENTS FILED IN CANCER VACCINES MARKET, BY DOCUMENT TYPE, 2014-2024
TABLE 8 LIST OF PATENTS IN CANCER VACCINES MARKET, 2023-2024
TABLE 9 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY TYPE, 2021-2023
TABLE 10 AVERAGE SELLING PRICE OF CANCER VACCINES, BY REGION, 2023
TABLE 11 KEY CONFERENCES & EVENTS, JUNE 2024-DECEMBER 2025
TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 CANCER VACCINES MARKET: PORTER'S FIVE FORCES ANALYSIS
TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
TABLE 19 KEY BUYING CRITERIA FOR TOP THREE END USERS
TABLE 20 IMPORT VALUE FOR HS CODE 300241, 2019-2023 (USD THOUSAND)
TABLE 21 IMPORT VOLUME FOR HS CODE 300241, 2019-2023 (TONS)
TABLE 22 EXPORT VALUE FOR HS CODE 300241, 2019-2023 (USD THOUSAND)
TABLE 23 EXPORT VOLUME FOR HS CODE 300241, 2019-2023 (TONS)
TABLE 24 CANCER VACCINES MARKET: PRODUCTS IN PIPELINE AND LAUNCH DATES
TABLE 25 CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 26 PREVENTIVE CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 27 NORTH AMERICA: PREVENTIVE CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 28 EUROPE: PREVENTIVE CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 29 ASIA PACIFIC: PREVENTIVE CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 30 LATIN AMERICA: PREVENTIVE CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 31 MIDDLE EAST: PREVENTIVE CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 32 THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 33 THERAPEUTIC CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 34 NORTH AMERICA: THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 35 EUROPE: THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 36 ASIA PACIFIC: THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 37 LATIN AMERICA: THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 38 MIDDLE EAST: THERAPEUTIC CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 39 NEOANTIGEN CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 40 NORTH AMERICA: NEOANTIGEN CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 41 EUROPE: NEOANTIGEN CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 42 ASIA PACIFIC: NEOANTIGEN CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 43 LATIN AMERICA: NEOANTIGEN CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 44 MIDDLE EAST: NEOANTIGEN CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 45 OTHER THERAPEUTIC CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 46 NORTH AMERICA: OTHER THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 47 EUROPE: OTHER THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 48 ASIA PACIFIC: OTHER THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 49 LATIN AMERICA: OTHER THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 50 MIDDLE EAST: OTHER THERAPEUTIC CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 51 CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 52 CELL-BASED CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 53 NORTH AMERICA: CELL-BASED CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 54 EUROPE: CELL-BASED CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 55 ASIA PACIFIC: CELL-BASED CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 56 LATIN AMERICA: CELL-BASED CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 57 MIDDLE EAST: CELL-BASED CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 58 RECOMBINANT CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 59 NORTH AMERICA: RECOMBINANT CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 60 EUROPE: RECOMBINANT CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 61 ASIA PACIFIC: RECOMBINANT CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 62 LATIN AMERICA: RECOMBINANT CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 63 MIDDLE EAST: RECOMBINANT CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 64 OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 65 NORTH AMERICA: OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 66 EUROPE: OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 67 ASIA PACIFIC: OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 68 LATIN AMERICA: OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 69 MIDDLE EAST: OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 70 CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 71 CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE, BY REGION, 2022-2032 (USD MILLION)
TABLE 72 NORTH AMERICA: CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 73 EUROPE: CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 74 ASIA PACIFIC: CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 75 LATIN AMERICA: CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 76 MIDDLE EAST: CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE, BY REGION, 2022-2032 (USD MILLION)
TABLE 77 CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022-2032 (USD MILLION)
TABLE 78 NORTH AMERICA: CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 79 EUROPE: CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 80 ASIA PACIFIC: CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 81 LATIN AMERICA: CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 82 MIDDLE EAST: CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022-2032 (USD MILLION)
TABLE 83 CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 84 CERVICAL & RELATED CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 85 NORTH AMERICA: CERVICAL & RELATED CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 86 EUROPE: CERVICAL & RELATED CANCER VACCINES MARKET, BY COUNTRY, 2022-2032(USD MILLION)
TABLE 87 ASIA PACIFIC: CERVICAL & RELATED CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 88 LATIN AMERICA: CERVICAL & RELATED CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 89 MIDDLE EAST: CERVICAL & RELATED CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 90 CANCER VACCINES MARKET FOR OTHER INDICATIONS, BY REGION, 2022-2032 (USD MILLION)
TABLE 91 NORTH AMERICA: CANCER VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 92 EUROPE: CANCER VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2032(USD MILLION)
TABLE 93 ASIA PACIFIC: CANCER VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 94 LATIN AMERICA: CANCER VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 95 MIDDLE EAST: CANCER VACCINES MARKET FOR OTHER INDICATIONS, BY REGION, 2022-2032 (USD MILLION)
TABLE 96 CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 97 CANCER VACCINES MARKET FOR HOSPITALS, BY REGION, 2022-2032 (USD MILLION)
TABLE 98 NORTH AMERICA: CANCER VACCINES MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 99 EUROPE: CANCER VACCINES MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 100 ASIA PACIFIC: CANCER VACCINES MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 101 LATIN AMERICA: CANCER VACCINES MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 102 MIDDLE EAST: CANCER VACCINES MARKET FOR HOSPITALS, BY REGION, 2022-2032 (USD MILLION)
TABLE 103 CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY REGION, 2022-2032 (USD MILLION)
TABLE 104 NORTH AMERICA: CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 105 EUROPE: CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 106 ASIA PACIFIC: CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 107 LATIN AMERICA: CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 108 MIDDLE EAST: CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY REGION, 2022-2032 (USD MILLION)
TABLE 109 CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 110 ASIA PACIFIC: KEY MACROINDICATORS
TABLE 111 ASIA PACIFIC: CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 112 ASIA PACIFIC: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 113 ASIA PACIFIC: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 114 ASIA PACIFIC: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 115 ASIA PACIFIC: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 116 ASIA PACIFIC: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 117 ASIA PACIFIC: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 118 CHINA: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 119 CHINA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 120 CHINA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 121 CHINA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 122 CHINA: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 123 CHINA: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 124 JAPAN: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 125 JAPAN: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 126 JAPAN: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 127 JAPAN: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 128 JAPAN: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 129 JAPAN: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 130 INDIA: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 131 INDIA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 132 INDIA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 133 INDIA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 134 INDIA: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 135 INDIA: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 136 SOUTH KOREA: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 137 SOUTH KOREA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 138 SOUTH KOREA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 139 SOUTH KOREA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 140 SOUTH KOREA: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 141 SOUTH KOREA: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 142 REST OF ASIA PACIFIC: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 143 REST OF ASIA PACIFIC: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 144 REST OF ASIA PACIFIC: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 145 REST OF ASIA PACIFIC: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 146 REST OF ASIA PACIFIC: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 147 REST OF ASIA PACIFIC: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 148 NORTH AMERICA: KEY MACROINDICATORS
TABLE 149 NORTH AMERICA: CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 150 NORTH AMERICA: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 151 NORTH AMERICA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 152 NORTH AMERICA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 153 NORTH AMERICA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 154 NORTH AMERICA: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 155 NORTH AMERICA: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 156 US: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 157 US: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 158 US: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 159 US: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 160 US: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 161 US: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 162 CANADA: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 163 CANADA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 164 CANADA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 165 CANADA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 166 CANADA: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 167 CANADA: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 168 EUROPE: KEY MACROINDICATORS
TABLE 169 EUROPE: CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 170 EUROPE: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 171 EUROPE: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 172 EUROPE: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 173 EUROPE: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 174 EUROPE: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 175 EUROPE: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 176 GERMANY: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 177 GERMANY: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 178 GERMANY: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 179 GERMANY: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 180 GERMANY: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 181 GERMANY: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 182 UK: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 183 UK: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 184 UK: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 185 UK: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 186 UK: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 187 UK: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 188 FRANCE: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 189 FRANCE: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 190 FRANCE: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 191 FRANCE: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 192 FRANCE: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 193 FRANCE: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 194 ITALY: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 195 ITALY: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 196 ITALY: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 197 ITALY: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 198 ITALY: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 199 ITALY: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 200 SPAIN: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 201 SPAIN: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 202 SPAIN: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 203 SPAIN: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 204 SPAIN: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 205 SPAIN: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 206 REST OF EUROPE: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 207 REST OF EUROPE: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 208 REST OF EUROPE: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 209 REST OF EUROPE: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 210 REST OF EUROPE: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 211 REST OF EUROPE: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 212 LATIN AMERICA: KEY MACROINDICATORS
TABLE 213 LATIN AMERICA: CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
TABLE 214 LATIN AMERICA: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 215 LATIN AMERICA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 216 LATIN AMERICA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 217 LATIN AMERICA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 218 LATIN AMERICA: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 219 LATIN AMERICA: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 220 BRAZIL: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 221 BRAZIL: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 222 BRAZIL: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 223 BRAZIL: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 224 BRAZIL: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 225 BRAZIL: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 226 MEXICO: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 227 MEXICO: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 228 MEXICO: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 229 MEXICO: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 230 MEXICO: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 231 MEXICO: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 232 REST OF LATIN AMERICA: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 233 REST OF LATIN AMERICA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 234 REST OF LATIN AMERICA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 235 REST OF LATIN AMERICA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 236 REST OF LATIN AMERICA: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 237 REST OF LATIN AMERICA: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 238 MIDDLE EAST: KEY MACROINDICATORS
TABLE 239 MIDDLE EAST: CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
TABLE 240 MIDDLE EAST: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 241 MIDDLE EAST: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 242 MIDDLE EAST: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 243 MIDDLE EAST: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 244 MIDDLE EAST: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 245 MIDDLE EAST: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 246 GCC COUNTRIES: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 247 GCC COUNTRIES: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 248 GCC COUNTRIES: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 249 GCC COUNTRIES: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 250 GCC COUNTRIES: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 251 GCC COUNTRIES: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 252 REST OF MIDDLE EAST: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 253 REST OF MIDDLE EAST: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 254 REST OF MIDDLE EAST: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 255 REST OF MIDDLE EAST: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 256 REST OF MIDDLE EAST: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 257 REST OF MIDDLE EAST: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 258 AFRICA: KEY MACROINDICATORS
TABLE 259 AFRICA: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 260 AFRICA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
TABLE 261 AFRICA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
TABLE 262 AFRICA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 263 AFRICA: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
TABLE 264 AFRICA: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
TABLE 265 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, 2021-2024
TABLE 266 CANCER VACCINES MARKET SHARE RANKING (2023)
TABLE 267 CANCER VACCINES MARKET SHARE RANKING (2032)
TABLE 268 CANCER VACCINES MARKET: REGION FOOTPRINT
TABLE 269 CANCER VACCINES MARKET: TYPE FOOTPRINT
TABLE 270 CANCER VACCINES MARKET: TECHNOLOGY FOOTPRINT
TABLE 271 CANCER VACCINES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
TABLE 272 CANCER VACCINES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 273 CANCER VACCINES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 274 CANCER VACCINES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-NOVEMBER 2024
TABLE 275 CANCER VACCINES MARKET: DEALS, JANUARY 2021-NOVEMBER 2024
TABLE 276 CANCER VACCINES MARKET: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
TABLE 277 MERCK: COMPANY OVERVIEW
TABLE 278 MERCK: PRODUCTS OFFERED
TABLE 279 MERCK: DEALS, JANUARY 2021-NOVEMBER 2024
TABLE 280 MERCK: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
TABLE 281 GSK: COMPANY OVERVIEW
TABLE 282 GSK: PRODUCTS OFFERED
TABLE 283 GSK: PRODUCT APPROVALS, JANUARY 2021-NOVEMBER 2024
TABLE 284 DENDREON PHARMACEUTICALS: COMPANY OVERVIEW
TABLE 285 DENDREON PHARMACEUTICALS: PRODUCTS OFFERED
TABLE 286 JW CREAGENE: COMPANY OVERVIEW
TABLE 287 JW CREAGENE: PRODUCTS OFFERED
TABLE 288 SERUM INSTITUTE OF INDIA: COMPANY OVERVIEW
TABLE 289 SERUM INSTITUTE OF INDIA: PRODUCTS OFFERED
TABLE 290 SERUM INSTITUTE OF INDIA: PRODUCT LAUNCHES, JANUARY 2021-NOVEMBER 2024
TABLE 291 SERUM INSTITUTE OF INDIA: DEALS, JANUARY 2021-NOVEMBER 2024
TABLE 292 VERITY PHARMACEUTICALS: COMPANY OVERVIEW
TABLE 293 VERITY PHARMACEUTICALS: PRODUCTS OFFERED
TABLE 294 VERITY PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2021-NOVEMBER 2024
TABLE 295 WANTAI BIOPHARM: COMPANY OVERVIEW
TABLE 296 WANTAI BIOPHARM: PRODUCTS OFFERED
TABLE 297 SHANGHAI ZERUN BIOTECHNOLOGY: COMPANY OVERVIEW
TABLE 298 SHANGHAI ZERUN BIOTECHNOLOGY: PRODUCTS OFFERED
TABLE 299 SHANGHAI ZERUN BIOTECHNOLOGY: PRODUCT APPROVALS, JANUARY 2021-NOVEMBER 2024
TABLE 300 VACCINOGEN: COMPANY OVERVIEW
TABLE 301 VACCINOGEN: PRODUCTS OFFERED
List of Figures
FIGURE 1 CANCER VACCINES MARKET SEGMENTATION
FIGURE 2 RESEARCH DESIGN
FIGURE 3 BREAKDOWN OF PRIMARIES: CANCER VACCINES MARKET
FIGURE 4 CANCER VACCINES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
FIGURE 5 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (PRODUCTS), 2023
FIGURE 6 ILLUSTRATIVE EXAMPLE OF MERCK & CO., INC.: REVENUE SHARE ANALYSIS (2023)
FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 9 CANCER VACCINES MARKET: CAGR PROJECTIONS
FIGURE 10 DATA TRIANGULATION METHODOLOGY
FIGURE 11 CANCER VACCINES MARKET, BY TYPE, 2024 VS. 2032 (USD MILLION)
FIGURE 12 CANCER VACCINES MARKET, BY TECHNOLOGY, 2024 VS. 2032 (USD MILLION)
FIGURE 13 CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024 VS. 2032 (USD MILLION)
FIGURE 14 CANCER VACCINES MARKET, BY INDICATION, 2024 VS. 2032 (USD MILLION)
FIGURE 15 CANCER VACCINES MARKET, BY END USER, 2024 VS. 2032 (USD MILLION)
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF CANCER VACCINES MARKET (2024-2032)
FIGURE 17 ADVANCEMENTS IN CANCER VACCINES AND RISING DEMAND FOR NEOANTIGEN CANCER VACCINES TO DRIVE MARKET
FIGURE 18 RECOMBINANT VACCINES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
FIGURE 19 PREVENTIVE VACCINES TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 20 US TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 21 CANCER VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 22 TRENDS/DISRUPTIONS INFLUENCING CUSTOMERS' BUSINESS
FIGURE 23 CANCER VACCINES MARKET: VALUE CHAIN ANALYSIS
FIGURE 24 CANCER VACCINES MARKET: ECOSYSTEM ANALYSIS
FIGURE 25 CANCER VACCINES MARKET: PATENT ANALYSIS
FIGURE 26 CANCER VACCINES MARKET: FUNDING SCENARIO
FIGURE 27 CANCER VACCINES MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 28 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS
FIGURE 29 KEY BUYING CRITERIA FOR TOP END USERS
FIGURE 30 CANCER VACCINES MARKET: IMPACT OF AI
FIGURE 31 ASIA PACIFIC: CANCER VACCINES MARKET SNAPSHOT
FIGURE 32 NORTH AMERICA: CANCER VACCINES MARKET SNAPSHOT
FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN CANCER VACCINES MARKET, 2019-2023
FIGURE 34 CANCER VACCINES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
FIGURE 35 CANCER VACCINES MARKET: COMPANY FOOTPRINT
FIGURE 36 CANCER VACCINES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
FIGURE 37 EV/EBITDA OF KEY VENDORS
FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 39 CANCER VACCINES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 40 MERCK: COMPANY SNAPSHOT (2023)
FIGURE 41 GSK: COMPANY SNAPSHOT (2023)
